Ketorolac for patients undergoing implant-based breast reconstruction: impact on hospital length of stay and postoperative narcotic use Journal Article uri icon
  • BACKGROUND: Opioid drugs have been a mainstay medication for the management of postoperative pain for several decades; however, in recent years there has been a push towards investigating alternative treatment options. Although ketorolac has been widely used by other medical and surgical specialties for analgesia, its utilization in plastic surgery has been widely debated. OBJECTIVES: The purpose of this study was to investigate the efficacy of ketorolac as an adjunct in postoperative pain management. METHODS: The authors performed a retrospective review of patients who underwent implant-based breast reconstruction after mastectomy between January 2012 and December 2016. Other risk factors, such as chronic anticoagulation, aspirin, or coagulopathies, were documented as well. RESULTS: There were 198 patients who met the inclusion criteria. The results demonstrated that patients who received ketorolac utilized significantly fewer narcotics than patients who did not: 80 mg vs 108.8 mg (P = 0.002), respectively. The results showed that patients who received ketorolac had a decreased length of hospitalization: 1.9 days vs 2.1 days (P = 0.04), respectively. CONCLUSIONS: Generous narcotic prescribing has received greater scrutiny in recent years. Aside from the risk of increased narcotic availability in the community, the side effects of nausea, puritis, and constipation delay patient recovery. These data show that patients who received ketorolac have a decreased length of hospital stay and lower narcotic use, suggesting ketorolac may be a safe and cost-effective adjustment to a multi-modal pain control regimen postoperatively.

  • Link to Article
    publication date
  • 2020
  • published in
  • Breast Cancer
  • Drugs and Drug Therapy
  • Pain
  • Retrospective Studies
  • Surgery
  • Additional Document Info
  • 40
  • issue
  • 2